Potential Therapeutic Benefits of Metformin Alone and in Combination with Sitagliptin in the Management of Type 2 Diabetes Patients with COVID-19

Type 2 diabetes mellitus (T2DM) is a potential risk factor for the development of COVID-19 and is associated with higher severity and mortality rates. T2DM patients are commonly treated with metformin monotherapy or metformin plus sitagliptin. In the present case-control, single-center cohort study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Kuraishy, Hayder M., Al-Gareeb, Ali I., Albogami, Sarah M., Jean-Marc, Sabatier, Nadwa, Eman Hassan, Hafiz, Amin A., A. Negm, Walaa, Kamal, Marwa, Al-Jouboury, Mohammed, Elekhnawy, Engy, Batiha, Gaber El-Saber, Waard, Michel De
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699540/
https://www.ncbi.nlm.nih.gov/pubmed/36355535
http://dx.doi.org/10.3390/ph15111361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699540/
https://www.ncbi.nlm.nih.gov/pubmed/36355535
http://dx.doi.org/10.3390/ph15111361

Ejemplares similares